Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$1.8M
Filings
26
Firms Hired
1
Active Period
2021–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Client expense: $10,000 · Firm income: —
Matched citations: S 765
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Client expense: $80,000 · Firm income: —
Matched citations: S 765
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Client expense: $80,000 · Firm income: —
Matched citations: S 765
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Client expense: $83,000 · Firm income: —
Matched citations: S 765
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority
Client expense: $75,000 · Firm income: —
Matched citations: S 2640
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Client expense: $75,000 · Firm income: —
Matched citations: S 765
HR 812 Inflation Reduction Act, including Defense Health, Viral Surveillance funding, COVID Supplemental allocations Consolidated Appropriations Act 2023 and affiliated draft bills, HHS funding, ASPR, AMD
Client expense: $90,000 · Firm income: —
Matched citations: HR 812
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority
Client expense: $90,000 · Firm income: —
Matched citations: S 2640
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Client expense: $90,000 · Firm income: —
Matched citations: S 765
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
2023 · first_quarter · Firm: HELIX, INC.
Viral sequencing derived from blood and spital, viral surveillance and COVID-19 not limited to issues in US H1425 Senate Ratification of Pandemic World Health Organization Agreements, planning for FY24 budget, and Pandemic All Hazards Preparedness Reauthorization. Issues related to biomarker testing, hereditary cancers, and pharmacogenomics including US S708 Medicaid Coverage for Major Depressive Disorders.
Client expense: $120,000 · Firm income: —
Matched citations: S708
HR 812 Inflation Reduction Act, including Defense Health, Viral Surveillance funding, COVID Supplemental allocations And funding needs, reauthorization for the ability for certain agencies to pull appropriations and enter into contracts in relation to the Pandemic & All Hazards Preparedness Act Discussion Drafts, including wastewater surveillance, viral surveillance and sequencing, data modernization, Center for Forecasting and Analytics, ASPR
Client expense: $130,000 · Firm income: —
Matched citations: HR 812
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures
Client expense: $130,000 · Firm income: —
Matched citations: S 2640
Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases. And the regulation of lab developed tests. US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing
Client expense: $130,000 · Firm income: —
Matched citations: S 765
US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments
Client expense: $130,000 · Firm income: —
Matched citations: S 765
Ending the Diagnostic Odyssey Act of 2021
2022 · fourth_quarter · Firm: HELIX, INC.
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Client expense: $100,000 · Firm income: —
Matched citations: S2022
Ending the Diagnostic Odyssey Act of 2021
2022 · fourth_quarter · Firm: HELIX, INC.
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Client expense: $100,000 · Firm income: —
Matched citations: S2022
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Client expense: $100,000 · Firm income: —
Matched citations: S236
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Client expense: $100,000 · Firm income: —
Matched citations: S236
Genomic research and testing, pandemic preparedness, viral surveillance, regulation of Lab Developed Tests in VALID ACT USH 4128 and PREVENT Act. Also US H 791 COVID-19 Variant Data Tracking, USH 6589 Clinical Trial Diversity. USH 7667 Rx Drug and Device User Fees, US S 236 COVID-19 Variants Program.
Client expense: $110,000 · Firm income: —
Matched citations: S 236
Ending the Diagnostic Odyssey Act of 2021
2022 · fourth_quarter · Firm: HELIX, INC.
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Client expense: $40,000 · Firm income: —
Matched citations: S2022
Ending the Diagnostic Odyssey Act of 2021
2022 · fourth_quarter · Firm: HELIX, INC.
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Client expense: $40,000 · Firm income: —
Matched citations: S2022
viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Client expense: $40,000 · Firm income: —
Matched citations: S236
Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)
Client expense: $40,000 · Firm income: —
Matched citations: S236
Source: Senate LDA